Nature Review Drug Discovery:新冠不减肿瘤免疫开发热度 老朋友的新篇章:二甲双胍再战抗肿瘤免疫 黎明前的黑暗——MET 抑制剂的失败案例 Science关注:警惕基因疗法副作用,“天使综合征”临床试验被叫停 Cell重磅进展:新方法可研究单RNA病毒的翻译和复制动态 CAR-NK细胞用于癌症治疗的新希望 季节因素影响抗病...
[11].Ji, L., et al., Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther, 2014. 36(1): p. 84-100.e9. [12]. Kannel WB, ,et al. Effect of weight on cardiovascular disease. Am J Cli...
The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug). ...
DapagliflozinwasapprovedbyCEDA(ChinaFoodAndDrugAdministration)in2017, servingasthefirstsodium-glucoseco-transporter2(SGLT2)inhibitorinChina. Dapagliflozinisorallyavailable,whichcanbeused asmonotherapyorasanadditiontoinsulinorotheroralagents,andcandecrease
[8] FDA Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2018. [9] Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in ...
SGLT2抑制剂的研发历程:从基础到临床.pptx,SGLT2抑制剂的研发历程:从基础到临床目录1SGLT2:肾脏最重要的葡萄糖转运体32家族性肾性糖尿症的启示SGLT2抑制剂的研发与药代动力学研究肾脏的生理: 尿液的形成血液重吸收Na+、Cl+、K+和水等物质分泌K+、H+、NH3集合管肾小球远曲
These are the primary mechanisms of action of the SGLT2-inhibitor class that have been purported to be responsible for its beneficial effects, however as our understanding of this drug class evolves there is a recognition that there may be other novel pathways at play – we explore these pathwa...
SGLT2抑制剂的研发历程：从基础到临床 SGLT2抑制剂的研发历程：从基础到临床 目录 1SGLT2：肾脏最重要的葡萄糖转运体2家族性肾性糖尿症的启示3SGLT2抑制剂的研发与药代动力学研究 肾脏的生理:尿液的形成 血液肾小球 重吸收Na+、Cl+、K+和水等物质分泌K+、H+、NH3 近曲小管 远曲小管 集合管 原尿 髓袢 尿...
Biopharm Drug Dispos. 2014 Oct;35(7):391-404. 加速尿酸排泄尿酸排泄率与尿糖浓度正相关增加尿糖浓度影响GLUT9亚型2 近端小管,高糖浓度反向激活GLUT9向细胞内转运糖,导致尿酸从细胞内排出增加在远端集合管,高糖浓度顺向抑制了尿酸的重吸收,导致尿酸重吸收减少 SGLT2 抑制剂机制三:降低血尿酸达格列净可降低血...
Keywords:Type2diabetes;Drugtherapy;Sodium-glucoseco-transporters;Inhibitors 薛耀明(1963-) 教授、主任医师、医学博士、博士生导师,现任南方医院 内分泌代谢科主任,兼任中国医师协会内分泌代谢科医师分会常委、广东省医学 会糖尿病分会副主任委员、广东省医学会内分泌分会副主任委员等职。培养博士 ...